This site is intended for health professionals only
The schizophrenia drug cariprazine being developed by Hungarian producer Richter Gedeon with Forest Laboratories is showing positive phase IIb test results, according to the company.
A spokesman reported: “For the primary endpoint, the Positive and Negative Syndrome Scale (PANSS), the data shows that patients with schizophrenia treated with cariprazine experience significant symptom improvement compared to placebo patients within the first week of treatment and at each subsequent time point studied.
“Based on this latest schizophrenia data, subject to a complete review of the full results, and the previously announced Phase II results in patients suffering from acute mania associated with bipolar I disorder, the companies intend to initiate Phase III trials for both indications in early 2010.”
Copyright Press Association 2009